China Health Big Data and Artificial Intelligence Industry Cooperation and Development Organization Files Prospectus

VCBeat (WeChat ID: vcbeat) has learned that on August 15, at the 2018 Sino-Pharmaceutical Summit International Forum on Health Big Data and Artificial Intelligence held in Boao, Hainan, the organizer, Sinopharm Information, joined forces with numerous institutions to establish the Preparatory Committee for the China Health Big Data and Artificial Intelligence Industry Cooperation and Development Organization. The committee plans to facilitate the formal establishment of the organization within the year, promote deep integration among industry, academia, and research, advance the application of big data and artificial intelligence technologies in the health sector in China, and actively support the implementation of the Healthy China strategy.

On March 5, 2017, the term “artificial intelligence” was mentioned for the first time in the Government Work Report, which called for accelerating the research, development, and commercialization of technologies such as artificial intelligence. Since then, a wave of supportive policies has been introduced in rapid succession, elevating “artificial intelligence” from a previously popular high-tech sector to a matter of national strategic importance.

The development and implementation of artificial intelligence are inseparable from the support of big data. The establishment of a national health information platform, the advent of national-level health and medical big data centers, and the pilot promotion of national health and medical big data centers and industrial parks all demonstrate the state’s emphasis on big data in the health industry.

In recent years, factors such as population aging and shifts in disease patterns have driven a corresponding transformation in the medical model, evolving from a traditional focus solely on treating diseases to a proactive approach centered on preventive care (“treating potential diseases before they manifest”) and health management. Professor Li Lanjuan, an Academician of the Chinese Academy of Engineering at Zhejiang University, stated that the medical model has expanded from the original “3P” framework to a more comprehensive “5P” model, encompassing Prevention, Prediction, Personalization, Participation, and Precision in healthcare organization. These changes necessitate the adoption of big data technologies and artificial intelligence for health management, with the aim of reducing disease incidence.

At the 2018 China Health Information Exchange (CHIE) Conference · International Summit on Health Big Data and Artificial Intelligence, numerous R&D experts from home and abroad in the fields of health big data and artificial intelligence delivered insightful presentations. Academician Zhong Shizhen of the Chinese Academy of Engineering, Professor Zhang Shaoxiang, President of the International Society for Digital Medicine, and Dr. Ling Zong, Senior Engineer at IBM, respectively introduced the methodologies and pathways for implementing digital medicine, data technologies, human body big data, and artificial intelligence in the medical field, along with related policies and ethical issues. Experts from institutions such as the Chinese Academy of Sciences, Peking University, Sun Yat-sen University, East China University of Science and Technology, Meinian Onehealth Healthcare, Philips, and Sinohealth Information Research Institute reported on the latest research advancements in big data and AI technologies from various dimensions and application scenarios. The forum showcased a vibrant diversity of technologies and products, creating an impression that the R&D landscape for health big data and artificial intelligence was flourishing and full of vitality. However, in stark contrast to this enthusiasm, the actual implementation and application of big data and AI technologies in China’s health sector remain limited.

Mr. Wu Han, President of Zhongkang Information, stated that beyond providing a forum for exchange at the Xipu Conference, it is essential to establish a permanent platform for collaboration and dialogue, jointly promoting the industrial leap forward in health big data and artificial intelligence. To better advance the application of big data and AI technologies in the health sector in China, the concept of establishing the “China Health Big Data and Artificial Intelligence Industry Cooperation and Development Organization” has emerged.

Mr. Wu Han, President of Zhongkang Information; Dr. Ning Yi, Executive Dean of the Peking University Meinian Public Health Research Institute; Dr. Ling Zong, Senior Engineer at IBM; Dr. Jiang Shuqiang from the Chinese Academy of Sciences; Mr. You Mao, Director of the General Affairs Division at the Health Development Research Center of the National Health Commission; Dr. Wang Shuyan from the Medical Services Department of the Guangzhou General Hospital of the People's Liberation Army; Mr. Wang Chunlin, CEO of Pan-China Financial Holdings Co., Ltd.; Mr. Feng Jianguo, Vice President of BGP Health Consulting Co., Ltd.; Mr. Peng Xiaodong, Secretary of the Board of Directors of Huaxia Life Insurance Co., Ltd.; Mr. Yu Hongshi, Assistant to the General Manager of Fude Sino Life Insurance Co., Ltd.; Professor Sun Hongyu from the Health Science Center of Peking University; and Professor Fan Zhigang from Sun Yat-sen University, among other distinguished guests, jointly attended the inauguration ceremony of the Preparatory Committee for the China Health Big Data and Artificial Intelligence Industry Cooperation and Development Organization.

At the inauguration ceremony, Wu Han, President of Zhongkang Information, called for recognition that, as one of the core directions for technological innovation in the health industry, the research, development, and application of big data and artificial intelligence (AI) will provide a powerful impetus to medical advancement. He expressed the hope that the industry would join hands with experts and scholars in big data and AI to jointly explore issues related to the research, development, ethics, and standards of big data and AI in the health sector, thereby accelerating the translation of technological achievements into practical applications.

As a leader empowering decision-making and connectivity across all stakeholders in the health industry, Zhongkang Information leverages its core competencies in data and technology to integrate industrial resources, enabling the comprehensive application of big data across pharmaceutical companies, healthcare providers, and patients. This approach ensures more precise decision-making and more efficient connectivity, contributing to the vision of a “Smart Health Industry and Smart Healthy Living.”